Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells.

[1]  J. Zha,et al.  Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy , 2010, Clinical Cancer Research.

[2]  F. López-Ríos,et al.  IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer , 2010, Oncogene.

[3]  G. Viglietto,et al.  The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[4]  M. Fukuoka,et al.  Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells , 2009, Clinical Cancer Research.

[5]  I. Herr,et al.  CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non‐small cell lung cancer patients , 2009, International journal of cancer.

[6]  A. Gualberto,et al.  Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. , 2009, Clinical lung cancer.

[7]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[8]  Xiangjiao Meng,et al.  Both CD133+ and CD133− subpopulations of A549 and H446 cells contain cancer‐initiating cells , 2009, Cancer science.

[9]  G. Mills,et al.  Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. , 2009, Cancer research.

[10]  B. Leyland-Jones,et al.  Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. , 2008, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[11]  H. Baker,et al.  ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells , 2008, Molecular Cancer.

[12]  D. Matei,et al.  Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. , 2008, Carcinogenesis.

[13]  K. Mimori,et al.  Cancer stem cells and chemoradiation resistance , 2008, Cancer science.

[14]  Anna E. Lokshin,et al.  Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties , 2008, PloS one.

[15]  M. Biffoni,et al.  Identification and expansion of the tumorigenic lung cancer stem cell population , 2008, Cell Death and Differentiation.

[16]  Eddie Reed,et al.  Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). , 2004, Oncology reports.

[17]  Hak Choy,et al.  International Journal of Radiation Oncology Biology Physics: Introduction , 2004 .

[18]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[19]  Li Mao,et al.  Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Pinchas Cohen,et al.  Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. , 2002, Cancer research.

[21]  M. King,et al.  Insulin-like Growth Factor-binding Protein-3 Modulates Expression of Bax and Bcl-2 and Potentiates p53-independent Radiation-induced Apoptosis in Human Breast Cancer Cells* , 2000, The Journal of Biological Chemistry.

[22]  J. Bourhis,et al.  Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II): role of Ku autoantigen. , 1999, Molecular pharmacology.

[23]  P. Scalliet,et al.  Resistance patterns between cis-diamminedichloroplatinum(II) and ionizing radiation. , 1991, Cancer research.

[24]  D. Ettinger,et al.  Ifosfamide in the treatment of non-small cell lung cancer. , 1989, Seminars in oncology.

[25]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[26]  F. Hofmann,et al.  The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy , 2005, Clinical Cancer Research.

[27]  C. Coughlin,et al.  Biologic and clinical developments of cisplatin combined with radiation: concepts, utility, projections for new trials, and the emergence of carboplatin. , 1989, Seminars in oncology.